文献速递心血管儿科影像MR

原研与仿制非罗莫司醇在两种给药方案下的比较:心脏MRI图像质量研究

Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study.
PubMed 文献 · Pediatr Radiol · 2023-10-14

该回顾性研究比较原研非罗莫司醇(BF)3 mg/kg、BF 2 mg/kg与仿制非罗莫司醇(GF)2 mg/kg三组在儿童及成人先天性心脏病患者中的安全性和心脏MRI图像质量,发现三组生命体征无统计学差异,无严重不良反应,GF 2 mg/kg组4D flow的VNR较BF 2 mg/kg组升高(P=0.005),作者结论为2 mg/kg GF与BF在安全性和图像质量方面无显著差异,但样本量小,需进一步研究确认。

要点

  • 2 mg/kg GF与2 mg/kg BF在MRA和4D flow定性评分均≥3分,SNR无统计学差异(P>0.05)。
  • 2 mg/kg GF组4D flow的VNR较2 mg/kg BF组升高(P=0.005)。
  • GF组不良反应发生率7.9%,BF 3 mg/kg组2.3%,BF 2 mg/kg组8.4%,无严重不良反应。

核心结论

  • 2 mg/kg GF与BF在安全性和图像质量方面无显著差异,但样本量小,需进一步研究确认。

研究设计与样本

  • IRB批准的回顾性研究,共3组:组1为3 mg/kg BF 216例(年龄19.29±11.71岁,范围2个月至62岁),组2为2 mg/kg BF 47例(年龄15.35±8.56岁,范围10天至41岁),组3为2 mg/kg GF 127例(年龄17.16±12.18岁,范围6天至58岁)。

诊断标准与关键数值

  • MRA图像质量定量分析采用信噪比(SNR),4D flow采用速度噪声比(VNR);定性分级由2名经验观察者完成,MRA和4D flow定性评分三组均≥3分。

临床应用与阅片要点

  • 作者结论认为2 mg/kg GF与BF在安全性和图像质量方面无显著差异,但鉴于样本量小,需进一步研究确认。

局限性

  • 样本量小。
  • 需进一步研究确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Ferumoxytol is becoming more widely used as an off-label blood-pool contrast agent for MR angiography (MRA) and four-dimensional (4D) flow imaging in pediatric cardiovascular disease. Brand and generic versions of ferumoxytol are available with no information on relative efficacy as a contrast agent and safety profiles.

OBJECTIVE: This study evaluates patient safety and image quality of comparable dosages of generic ferumoxytol (GF) versus brand ferumoxytol (BF) with the following hypotheses: (1) Reducing the contrast dosage from 3 to 2 mg/kg will not affect imaging quality and diagnostic accuracy of MRA and four-dimensional 4D flow. (2) GF and BF have similar image quality. (3) GF and BF have similar patient safety profiles.

MATERIALS AND METHODS: In an IRB-approved retrospective study, changes in vitals/clinical status between baseline, during infusion, and 30 min post-infusion were analyzed in 3 groups: group 1 (3 mg/kg BF, 216 patients, age: 19.29 ± 11.71 years ranging from 2 months to 62 years), group 2 (2 mg/kg BF, 47 patients, age: 15.35 ± 8.56 years ranging from 10 days to 41 years), and group 3 (2 mg/kg GF, 127 patients, age: 17.16 ± 12.18 years ranging from 6 days to 58 years). Both pediatric and adult patients with congenital heart disease (CHD) indications were included within the study. Adverse reactions were classified as mild, moderate, or severe. Quantitative analysis of MR image quality was performed with signal-to-noise ratio (SNR) on MRA and velocity-to-noise ratio (VNR) on 4D flow. Qualitative grading of imaging features was performed by 2 experienced observers. Two-way analysis of variance (ANOVA) and chi-square tests were used for comparison with a P value of ≤ 0.05 used for significance.

RESULTS: No statistical difference was found in clinical status and vital signs (P>0.05). No severe reactions were reported. 7.9% of GF patients experienced an adverse reaction compared to 2.3% with 3 mg/kg BF and 8.4% with 2 mg/kg BF. There was no statistical difference in SNR between the 3 groups (P>0.05). For 4D flow, 2 mg/kg GF demonstrated an increase in VNR compared to 2 mg/kg BF (P = 0.005). The qualitative scores for MRA and 4D flow were high (≥ 3) across all 3 groups.

CONCLUSIONS: No significant difference was identified between 2 mg/kg GF and BF in terms of safety profile and image quality. Given the small sample size of this study, further studies are required to confirm these results.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Dasi A, Kring DN, Selvaraj B, et al. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study. Pediatr Radiol. 2023. PMID: 37837456. doi:10.1007/s00247-023-05778-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。